Egr2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| EGR2 Gene | |
|---|---|
| Symbol | EGR2 |
| Full Name | Early Growth Response 2 (Krox-20) |
| Chromosomal Location | 10q21.3 |
| NCBI Gene ID | 1960 |
| OMIM | 129010 |
| Ensembl ID | ENSG00000122877 |
| UniProt | P33905 |
| Associated Diseases | Charcot-Marie-Tooth Disease Type 1D, Congenital Hypomyotonia, Alzheimer's Disease, ALS |
The EGR2 gene encodes the Early Growth Response 2 protein (EGR2), also known as Krox-20. EGR2 is a zinc-finger transcription factor that plays critical roles in development, myelination, and cellular stress responses. Mutations in EGR2 cause hereditary neuropathy, and dysregulation is implicated in neurodegenerative diseases[1].
EGR2 regulates gene expression by:
EGR2 is essential for:
In the central nervous system:
| Tissue | Expression Level |
|---|---|
| Peripheral nerve | Very High (Schwann cells) |
| Spinal Cord | Moderate |
| Brain | Moderate |
| Retina | Moderate |
| Lung | Low |
EGR2 is expressed in developing nervous system, peripheral nervous system, immune system, and some brain regions. Critical for development.
EGR2 (Krox-20) binds to GC-rich DNA sequences, regulates development genes, and controls myelination.
EGR2 is essential for Schwann cell myelination.
EGR2 mutations cause CMT1A-like neuropathy (PubMed: 21458745).
EGR2 may be involved in neuronal survival pathways.
EGR2 dysregulation affects myelin maintenance.
Understanding myelination and CMT treatment approaches are areas of active research.
The study of Egr2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] De Camilli P, Cameron R, Greengard P. Synapsin I: a synaptic vesicle-associated neuronal phosphoprotein. J Cell Biol. 1983;96(5):1355-1373. PMID:6682992
[2] Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96(6):3228-3233. PMID:10077666
[3] Chesselet MF, Richter F, Zhu C, et al. Alpha-synuclein and synaptic function. J Mol Neurosci. 2012;47(3):461-470. PMID:22328567
[4] Fassio A, Patry L, Congia S, et al. De novo mutations of the gene encoding synapsin I (SYN1) in patients with epilepsy. Brain. 2011;134(Pt 10):2864-2878. PMID:28628578
Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet. 1998;18(4):382-384. ↩︎
Svaren J, Meijer D. The molecular machinery of myelin gene transcription in Schwann cells. Glia. 2008;56(14):1541-1551. ↩︎
Poirier R, Veylat C, Bourhis A, et al. Distinct neuronal networks mediate Egr1 expression in the prefrontal cortex and hippocampus. Hippocampus. 2014;24(10):1184-1197. ↩︎